Big pharma doesn't want to take on the risk with a

Big pharma doesn't want to take on the risk with any products until they are proven- usually with at least positive phase 2 trial results. Once ESS has some initial positive data, my guess is there will be a lot of interest, but not yet- just too much risk. I spoke to Gregg Linn last Jan about OvaDx- he met with Roche and they told him to come back once it was approved by the FDA.

I am guessing the partner for ESS is a smaller co. and they are not offering much up front cash. Hopefully though its enough to appease the toxics for a while and get us to initial data. If we can do that, it will be a turning point for the co.